dolutegravir exposure

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Periconceptional dolutegravir exposure was not associated with an increased risk of neural tube defects in live-born infants in either the MarketScan or Medicaid US databases, with zero NTD cases amon

Effect: null; NTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)

Periconceptional dolutegravir exposure was not associated with an increased risk of neural tube defects in live-born infants in either the MarketScan or Medicaid US databases, with zero NTD cases amon

Effect: null; NTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)

Periconceptional dolutegravir exposure was not associated with an increased risk of neural tube defects in live-born infants in either the MarketScan or Medicaid US databases, with zero NTD cases amon

Effect: null; NTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)

Periconceptional dolutegravir exposure was not associated with an increased risk of neural tube defects in live-born infants in either the MarketScan or Medicaid US databases, with zero NTD cases amon

Effect: null; NTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)

Periconceptional dolutegravir exposure was not associated with an increased risk of neural tube defects in live-born infants in either the MarketScan or Medicaid US databases, with zero NTD cases amon

Effect: null; NTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)

Periconceptional dolutegravir exposure was not associated with an increased risk of neural tube defects in live-born infants in either the MarketScan or Medicaid US databases, with zero NTD cases amon

Effect: null; NTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)

Periconceptional dolutegravir exposure was not associated with an increased risk of neural tube defects in live-born infants in either the MarketScan or Medicaid US databases, with zero NTD cases amon

Effect: null; NTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)

Periconceptional dolutegravir exposure was not associated with an increased risk of neural tube defects in live-born infants in either the MarketScan or Medicaid US databases, with zero NTD cases amon

Effect: null; NTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)

Periconceptional dolutegravir exposure was not associated with an increased risk of neural tube defects in live-born infants in either the MarketScan or Medicaid US databases, with zero NTD cases amon

Effect: null; NTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)

Periconceptional dolutegravir exposure was not associated with an increased risk of neural tube defects in live-born infants in either the MarketScan or Medicaid US databases, with zero NTD cases amon

Effect: null; NTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)

Periconceptional dolutegravir exposure was not associated with an increased risk of neural tube defects in live-born infants in either the MarketScan or Medicaid US databases, with zero NTD cases amon

Effect: null; NTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)

Periconceptional dolutegravir exposure was not associated with an increased risk of neural tube defects in live-born infants in either the MarketScan or Medicaid US databases, with zero NTD cases amon

Effect: null; NTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)

Periconceptional dolutegravir exposure was not associated with an increased risk of neural tube defects in live-born infants in either the MarketScan or Medicaid US databases, with zero NTD cases amon

Effect: null; NTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)

Periconceptional dolutegravir exposure was not associated with an increased risk of neural tube defects in live-born infants in either the MarketScan or Medicaid US databases, with zero NTD cases amon

Effect: null; NTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)

Periconceptional dolutegravir exposure was not associated with an increased risk of neural tube defects in live-born infants in either the MarketScan or Medicaid US databases, with zero NTD cases amon

Effect: null; NTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)

Periconceptional dolutegravir exposure was not associated with an increased risk of neural tube defects in live-born infants in either the MarketScan or Medicaid US databases, with zero NTD cases amon

Effect: null; NTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)

Periconceptional dolutegravir exposure was not associated with an increased risk of neural tube defects in live-born infants in either the MarketScan or Medicaid US databases, with zero NTD cases amon

Effect: null; NTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)

Periconceptional dolutegravir exposure was not associated with an increased risk of neural tube defects in live-born infants in either the MarketScan or Medicaid US databases, with zero NTD cases amon

Effect: null; NTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)

Periconceptional dolutegravir exposure was not associated with an increased risk of neural tube defects in live-born infants in either the MarketScan or Medicaid US databases, with zero NTD cases amon

Effect: null; NTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)

Periconceptional dolutegravir exposure was not associated with an increased risk of neural tube defects in live-born infants in either the MarketScan or Medicaid US databases, with zero NTD cases amon

Effect: null; NTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)

Periconceptional dolutegravir exposure was not associated with an increased risk of neural tube defects in live-born infants in either the MarketScan or Medicaid US databases, with zero NTD cases amon

Effect: null; NTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)

Periconceptional dolutegravir exposure was not associated with an increased risk of neural tube defects in live-born infants in either the MarketScan or Medicaid US databases, with zero NTD cases amon

Effect: null; NTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)

Periconceptional dolutegravir exposure was not associated with an increased risk of neural tube defects in live-born infants in either the MarketScan or Medicaid US databases, with zero NTD cases amon

Effect: null; NTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)